OSC provides 3-year funding to Prosper Canada
"Prosper Canada champions financial literacy and empowerment through education, research and outreach," said Grant Vingoe, OSC CEO. "By providing funding to Prosper Canada, we are investing in Ontarians and ensuring they have access to the resources and support to navigate the complexities of the financial landscape."
The $5.4-million funding will be allocated over a period of three years. The funding will be used by Prosper Canada to support the provision of tailored financial education and counselling to Ontarians living on low and moderate incomes, and to work with Indigenous community partner organizations to develop tailored financial resources and support that meets the unique needs of Indigenous community members.
The mandate of the OSC is to provide protection to investors from unfair, improper or fraudulent practices, to foster fair, efficient and competitive capital markets and confidence in the capital markets, to foster capital formation, and to contribute to the stability of the financial system and the reduction of systemic risk. Investors are urged to check the registration of any persons or company offering an investment opportunity and to review the OSC investor materials available at https://www.osc.ca.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
38 minutes ago
- Cision Canada
LSL PHARMA GROUP ANNOUNCES THE COMPLETION OF EARLY REDEMPTION OF ALL 11% UNSECURED CONVERTIBLE DEBENTURES
BOUCHERVILLE, QC, Aug. 4, 2025 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) (" LSL Pharma" or the " Corporation"), a Canadian integrated pharmaceutical company, today announced that it has completed the early redemption and cancellation of all issued and outstanding 11.0% Unsecured Convertible Debentures (originally scheduled to mature on October 31, 2028) (the " Debentures"). Pursuant to the Company's announcement on July 2, 2025, Debenture holders were paid an aggregate amount of $3,505,098.08, representing (i) $3,288,000 as the principal amount of the Debentures, (ii) the early repayment premium pursuant to the trust indenture dated November 1, 2023 between the Corporation and the Trustee ,TSX Trust Company and (iii) all accrued and unpaid interest up to but excluding the Redemption Date. As a result of the early redemption, all Debentures, previously listed on the TSX Venture Exchange (" TSXV") under the symbol were delisted and have ceased trading on August 1, 2025, in accordance with TSXV policies. ABOUT LSL PHARMA GROUP INC. LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and commercialization of high-quality sterile ophthalmic pharmaceutical products, as well as pharmaceutical, cosmetic and natural health products in solid, semi-solid and liquid dosage forms. Companies forming part of LSL Pharma Group include Steri-Med Pharma Inc., LSL Laboratory Inc., Virage Santé Inc. and Dermolab Pharma Ltd. For further information, please visit our website at CAUTION REGARDING FORWARD-LOOKING STATEMENTS This press release may contain forward-looking statements as defined under applicable Canadian securities legislation. Forward-looking statements can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "continue" or similar expressions. Forward-looking statements are based on a number of assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Corporation's ability to control or predict, that could cause actual results or performance to differ materially from those expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, those identified in the Corporation's filings with Canadian securities regulatory authorities, such as legislative or regulatory developments, increased competition, technological change and general economic conditions. All forward-looking statements made herein should be read in conjunction with such documents. Readers are cautioned not to place undue reliance on forward-looking statements. No assurance can be given that any of the events referred to in the forward-looking statements will transpire, and if any of them do, the actual results, performance or achievements of the Corporation may differ materially from those expressed or implied by the forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. The Corporation does not undertake to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) have reviewed or accept responsibility for the adequacy or accuracy of this release. SOURCE Groupe LSL PHARMA INC.
an hour ago
Champagne, Anand travelling to Mexico to strengthen Canada's trade ties: sources
Finance Minister François-Philippe Champagne says he and Foreign Affairs Minister Anita Anand will be travelling to Mexico City to look at strengthening Canada's economic partnership with Mexico. The meetings will be constructive in that respect — looking at markets, looking at diversification, looking at strengthening our partnership with our Mexican colleagues, Champagne told Radio-Canada in Trois-Rivières, Que., on Monday afternoon. The news was first reported Sunday evening by the Globe and Mail. Two senior Canadian government sources told CBC News the meetings are happening tomorrow and Wednesday. The ministers are expected to return to Canada on Thursday. The sources say the goal of the visit is to advance Canada's bilateral relationship with Mexico and strengthen trade ties. Champagne and Anand are expected to meet with Mexican President Claudia Sheinbaum on Tuesday morning. Enlarge image (new window) Sheinbaum at the inauguration of a community hospital in Vicam, Sonora state, Mexico in mid-July. On Thursday, Trump posted on social media that he and Sheinbaum had agreed extend an existing trade deal for 90 days. Photo: Reuters / Mexico Presidency Champagne said the visit is all complementary to what we've been saying — that we need to engage with strategic partners around the world. And if you look at the [U.S.-Mexico-Canada Agreement] as a trading bloc, that's the second-largest trading bloc in the world. So it is important for us to engage with our Mexican friends, the finance minister added. One source told CBC that the trip is all about relationship building and the two ministers' expected meeting with Sheinbaum will lay the groundwork for a future bilateral meeting between the Mexican president and Prime Minister Mark Carney. Carney and Sheinbaum have spoken at least four times since the prime minister came into office. In June, the two met at the G7 Leaders' Summit in Alberta. A press release posted on Carney's website (new window) said he and Sheinbaum agreed to deepen bilateral collaboration at the ministerial level and they looked forward to meeting again in Mexico in the coming months. Trump extends tariff deal with Mexico The Canadians' visit comes days after U.S. President Donald Trump announced he had agreed with Sheinbaum to extend an existing trade deal with Mexico for 90 days and continue talks over the period with a goal of signing a new deal. Mexico will continue to pay a 25% Fentanyl Tariff, 25% Tariff on Cars, and 50% Tariff on Steel, Aluminum and Copper, Trump said in a Truth Social post. Additionally, Mexico has agreed to immediately terminate its Non Tariff Trade Barriers, of which there were many. Enlarge image (new window) Carney, Trump and Sheinbaum will renegotiate the trilateral free trade pact known as the U.S.-Canada-Mexico Agreement in 2026. Photo: Spencer Colby/The Canadian Press, Marco Ugarte/The Associated Press, Manuel Balce Ceneta/The Associated Press Canada did not get an extension. Trump signed an executive order raising tariffs on Canadian goods that are not compliant with USMCA to 35 per cent. The carve-out for USMCA-compliant goods means very few Canadian products will actually be subjected to the elevated tariff. The U.S. president criticized Canada's lack of co-operation in curbing the flow of fentanyl southward and for retaliating against his existing tariffs. On Sunday, Canada-U.S. Trade Minister Dominic LeBlanc said he expects (new window) Carney and Trump will have a conversation with each other over the next couple of days. LeBlanc left Washington earlier this week without a trade deal, but he told host Margaret Brennan, host of CBS's Face The Nation, that he came out of discussions "with a better understanding of the American concerns in the trading relationship. So we're prepared to stick around and do the work needed, LeBlanc added. With files from Philip Ling
Cision Canada
2 hours ago
- Cision Canada
5N Plus Inc. Reports 2025 Second Quarter Financial Results and Increases Annual Guidance
32% year-over-year revenue growth to a ten year-high of $184.2 million for the first half of 2025 Record Q2 2025 Adjusted gross margin 1 of $33.0 million and of 34.6% as a percentage of sales 1 Record Q2 2025 Adjusted EBITDA 1 of $24.1 million, representing 79% year-over-year growth Net-debt-to-EBITDA ratio 1 of 1.09x as at June 30, 2025 2025 Adjusted EBITDA guidance increased to a range of $65-$70 million, up from $55-$60 million MONTREAL, Aug. 4, 2025 /CNW/ - 5N Plus Inc. (TSX: VNP) ("5N+" or "the Company"), a leading global producer of specialty semiconductors and performance materials, today announced its financial results for the three-month period ended June 30, 2025 ("Q2 2025"). All amounts in this press release are expressed in U.S. dollars unless otherwise stated. "Our performance this quarter and year to date marks several new all-time highs for 5N+, including record quarterly Adjusted gross margin, and record quarterly and first-half Adjusted EBITDA. In addition, we generated our strongest first-half revenues in a decade. In a volatile business environment where customers are seeking dependable partners, 5N+ stands out for reliability, technical expertise and product quality, further supported by our diversified global sourcing and manufacturing capabilities which are of strategic importance to our customers," said Gervais Jacques, President and CEO, 5N+. "Building on our record results to date and amid accelerating demand in our strategic sectors, 2025 is shaping up to be a landmark year for 5N+. Within Specialty Semiconductors, we continue to capitalize on, and to anticipate, further demand momentum from the renewable energy and space power markets, while in Performance Materials our bismuth-based products are delivering exceptional margins," added Mr. Jacques. "As we head into the second half of the year, we are not only well-positioned to deliver on our now increased Adjusted EBITDA guidance ambitions for 2025, but to build on this momentum going into 2026. Thanks to our competitive advantages and expanded capacity, we will continue to solidify our status as the strategic partner of choice outside of China, able to capture growing demand for our high-purity advanced materials in an evolving geopolitical landscape," concluded Mr. Jacques. Financial Highlights Revenue in Q2 2025 increased by 28% to $95.3 million, compared to $74.6 million in Q2 2024. The increase is primarily attributable to higher sales in the terrestrial renewable energy and space solar power sectors under Specialty Semiconductors, and higher bismuth-based product pricing under Performance Materials. Adjusted EBITDA in Q2 2025 increased by 79% to $24.1 million, compared to $13.5 million in Q2 2024, driven by higher volumes in the terrestrial renewable energy and space solar power sectors, and better prices over inflation for both solar power and bismuth-based products. Adjusted gross margin increased by 41% to $33.0 million in Q2 2025, favourably impacted by the same factors as above. Adjusted gross margin as a percentage of sales was 34.6% in Q2 2025, compared to 31.3% in Q2 2024. Net earnings in Q2 2025 were $15.2 million, compared to $4.8 million in Q2 2024. Backlog 1 stood at $310.0 million, representing 297 days of annualized revenue as at June 30, 2025, 29 days higher than in the previous quarter. Net debt 1 was $74.3 million as at June 30, 2025, compared to $100.1 million as at December 31, 2024, reflecting an increase in cash. The Company's net-debt-to-EBITDA ratio stood at 1.09x as at June 30, 2025. ______________________________ 1 These measures are not recognized measures under IFRS and do not have standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures presented by other companies. See Non-IFRS Measures for more information. Outlook Through the second half of 2025, 5N+ anticipates demand under Specialty Semiconductors from the terrestrial renewable energy and space solar power markets to accelerate, as customers look to secure advanced materials from trusted and reliable partners. Under Performance Materials, consistent with historical trends, volumes through the second half of 2025 are expected to be slightly lower than compared to the first half of 2025, with margins continuing to benefit from the Company's strategic global footprint and sourcing capabilities in the current volatile business environment. Based on its financial performance year to date, coupled with anticipated demand under Specialty Semiconductors and better than anticipated performance under Performance Materials, Adjusted EBITDA guidance for 2025 has been revised upwards from a range of $55 to $60 million, last updated on February 25, 2025, to a range of $65 to $70 million. Looking ahead, the Company will continue to remain prudent in an evolving geopolitical environment, including with regards to its impact on operating costs. As a preferred supplier of ultra-high-purity, high-quality products with a strong supply chain providing customers with a key strategic advantage, 5N+ is well-positioned to continue solidifying its leadership in key end markets through the end of 2025 and going into 2026. Conference Call 5N+ will host a conference call on Tuesday, August 5, 2025, at 8:00 a.m. Eastern Daylight Time to discuss its 2025 second quarter financial results. All interested parties are invited to participate in the live broadcast on the Company's website at To participate in the conference call: A replay of the conference call will be available two hours after the event and until August 12, 2025. To access the recording, please dial 1-888-660-6345 and enter access code 94154. About 5N+ 5N+ is a leading global producer of specialty semiconductors and performance materials. The Company's ultra–pure materials often form the core element of its customers' products. These customers rely on 5N+'s products to enable performance and sustainability in their own products. 5N+ deploys a range of proprietary and proven technologies to develop and manufacture its products. The Company's products enable various applications in several key industries, including renewable energy, security, space, pharmaceutical, medical imaging and industrial. Headquartered in Montréal, Quebec, 5N+ operates R&D, manufacturing and commercial centers in strategically located facilities around the world including Europe, North America and Asia. Forward–Looking Statements Certain statements in this press release may be forward–looking within the meaning of applicable securities laws. Such forward–looking statements are based on a number of estimates and assumptions that the Company believes are reasonable when made, including that 5N+ will be able to retain and hire key personnel and maintain relationships with customers, suppliers and other business partners, that 5N+ will continue to operate its business in the normal course, that 5N+ will be able to implement its growth strategy, that 5N+ will be able to successfully and timely complete the realization of its backlog, that 5N+ will not suffer any supply chain challenges or any material disruption in the supply of raw materials on competitive terms, that 5N+ will be able to generate new sales, produce, deliver, and sell its expected product volumes at the expected prices and control its costs, as well as other factors believed to be appropriate and reasonable in the circumstances. However, there can be no assurance that such estimates and assumptions will prove to be correct. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict and may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward–looking statements. A description of the risks affecting the Company's business and activities appears under the heading "Risk and Uncertainties" of 5N+'s 2024 MD&A dated February 25, 2025 and note 10 of the unaudited condensed interim consolidated financial statements for the three and six-month periods ended June 30, 2025 and June 30, 2024 available on SEDAR+ at Forward–looking statements can generally be identified by the use of terms such as "may", "should", "would", "believe", "expect", the negative of these terms, variations of them or any similar terms. No assurance can be given that any events anticipated by the forward–looking statements in this press release will transpire or occur, or if any of them do so, what benefits that 5N+ will derive therefrom. In particular, no assurance can be given as to the future financial performance of 5N+. The forward–looking statements contained in this press release is made as of the date hereof and the Company has no obligation to publicly update such forward–looking information to reflect new information, subsequent or otherwise, unless required by applicable securities laws. The reader is warned against placing undue reliance on these forward–looking statements. Forward-looking statements are presented in this press release for the purpose of assisting investors and others in understanding certain key elements of the Company's expected financial results, as well as the Company's objectives, strategic priorities and outlook, and in obtaining a better understanding of the Company's anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. Three months Six months 2025 2024 2025 2024 $ $ $ $ Revenue 95,311 74,580 184,199 139,599 Cost of sales 65,888 54,385 127,780 102,405 Selling, general and administrative expenses 7,699 8,717 16,259 16,034 Other expenses (income), net 2,251 2,329 5,576 4,579 75,838 65,431 149,615 123,018 Operating earnings 19,473 9,149 34,584 16,581 Financial expense Interest on long-term debt 2,002 2,146 4,006 3,941 Imputed interest and other interest expense 351 (272) 1,064 139 Foreign exchange (gain) loss (97) 2 (811) (385) 2,256 1,876 4,259 3,695 Earnings before income taxes 17,217 7,273 30,325 12,886 Income tax expense (recovery) Current 4,706 2,177 8,077 4,691 Deferred (2,716) 307 (2,552) 899 1,990 2,484 5,525 5,590 Net earnings 15,227 4,789 24,800 7,296 Basic earnings per share 0.17 0.05 0.28 0.08 Diluted earnings per share 0.17 0.05 0.28 0.08 Net earnings are completely attributable to equity holders of 5N Plus Inc. 5N PLUS INC. INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (in thousands of United States dollars) (unaudited) June 30 2025 December 31 2024 $ $ Assets Current Cash 48,624 22,142 Accounts receivable 58,485 42,172 Inventories 142,960 137,823 Income tax receivable 850 1,811 Derivative financial assets 3,131 6,978 Other current assets 5,895 6,469 Total current assets 259,945 217,395 Property, plant and equipment 93,584 85,995 Right-of-use assets 29,373 28,583 Intangible assets 24,213 22,929 Goodwill 12,032 10,665 Deferred tax assets 9,439 7,358 Other assets 3,350 3,982 Total non-current assets 171,991 159,512 Total assets 431,936 376,907 Liabilities Current Trade and accrued liabilities 50,916 42,116 Income tax payable 10,733 5,207 Current portion of deferred revenue 13,834 11,206 Current portion of lease liabilities 2,115 1,952 Total current liabilities 77,598 60,481 Long-term debt 122,961 122,203 Deferred tax liabilities 6,216 5,737 Employee benefit plan obligations 13,272 12,624 Lease liabilities 28,856 27,450 Deferred revenue 10,103 8,688 Other liabilities 797 706 Total non-current liabilities 182,205 177,408 Total liabilities 259,803 237,889 Equity 172,133 139,018 Total liabilities and equity 431,936 376,907 Non–IFRS Measures Backlog represents the expected orders the Company has received, but has not yet executed, and that are expected to translate into sales within the next twelve months, expressed in dollars and estimated in number of days not to exceed 365 days. Bookings represent orders received during the period considered, expressed in number of days, and calculated by adding revenue to the increase or decrease in backlog for the period considered, divided by annualized year revenue. 5N+ uses backlog to provide an indication of expected future revenue in days, and bookings to determine its ability to sustain and increase its revenue. EBITDA means net earnings (loss) before interest expenses, income tax expense (recovery), depreciation and amortization. 5N+ uses EBITDA because it believes it is a meaningful measure of the operating performance of its ongoing business, without the effects of certain expenses. The definition of this non-IFRS measure used by the Company may differ from that used by other companies. EBITDA is reconciled to the most comparable IFRS measure: EBITDA margin is defined as EBITDA divided by revenue. Adjusted EBITDA means operating earnings (loss) as defined before the effect of impairment of inventories, share-based compensation expense (recovery), ERP implementation costs, loss (gain) on disposal of property, plant and equipment, loss (gain) on remeasurement of financial instrument, impairment (reversal of impairment) of non-current assets, litigation and restructuring costs (income), and depreciation and amortization. 5N+ uses Adjusted EBITDA because it believes it is a meaningful measure of the operating performance of its ongoing business without the effects of certain expenses. The definition of this non-IFRS measure used by the Company may differ from that used by other companies. Adjusted EBITDA margin is defined as Adjusted EBITDA divided by revenue. Adjusted EBITDA and Adjusted EBITDA margin are reconciled to the most comparable IFRS measure: Adjusted gross margin is a measure used to monitor the sales contribution after paying cost of sales, excluding depreciation and inventory impairment charges. 5N+ also expressed this measure in percentage of revenue by dividing the adjusted gross margin value by the total revenue. Adjusted gross margin is reconciled to the most comparable IFRS measure: Net debt is calculated as total debt less cash. Any introduced IFRS 16 reporting measures in reference to lease liabilities are excluded from the calculation. 5N+ uses this measure as an indicator of its overall financial position. The net debt to EBITDA ratio is defined as net debt divided by the trailing 12 months EBITDA. Total debt and Net debt are reconciled to the most comparable IFRS measure: SOURCE 5N Plus Inc.
